Key populations brief
Accessed November 2017
Global Plan to end TB 2016-2020
Situation Overview & Humanitarian Needs | July – September 2017
Key populations brief
Accessed 2017
AIDS Behav (2017) 21:S23–S33 DOI 10.1007/s10461-016-1670-9
The Community Action Research on Disability (CARD) programme in Uganda embraced and modified the EDR approach, recognising the need for including people with disability in the research process from concept to outcome, and nurturing participation and collaboration between all the stakeholders in achi...eving action-based research. T
more
Each unit builds on the one prior, and they all combine to provide key information for developing an SBCC strategy. It is not essential, however, to work through the I-Kit from start to finish. Users can choose to focus on specific aspects for which they need support in their emergency communication... response. The nine units and corresponding worksheets are outlined in the I-Kit Site Navigator.
more
Treating children infected with intestinal worms is one of the simplest and most cost–effective ways to improve their health.
The recommendations are intended for a wide audience, including policy-makers and their expert advisers as well as technical and programme staff at government institution...s and organizations involved in the design, implementation and expansion of programmes to control soil-transmitted helminth infections.
more
23rd February 2017, Protea Hotel Thuringerhof, Windhoek | 2017 Namibia ART Guidelines: Summary of New and Old Recommendations
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more